Abstract: Disclosed are compound, its stereoisomer, salt, hydrate, solvate, isotope or crystalline form thereof, represented by Formula (I), with X, R1, R2, R3, R4 and R5 as disclosed herein. Also, disclosed is a process for their preparation, compositions containing such compounds, methods of medical treatment or prophylaxis of a disease by such compounds and uses thereof. The compounds of Formula (I) are pyridoxal-5-phosphate (P5P) analogs, and can act as prodrugs.

Abstract: The present invention provides a titratable transdermal drug delivery system comprising an effective dose of an antithrombotic agent, such as tirofiban, or a pharmaceutically acceptable salt thereof. The dosage of the drug delivered is proportional to the size of the patch applied and achieves 60-85% platelet inhibition. The system enables and individualized treatment for patients. Also provided are methods for the treatment of various disorders where platelet inhibition is desired.

Abstract: The present invention provides a titratable transdermal drug delivery system comprising an effective dose of an antithrombotic agent, such as tirofiban, or a pharmaceutically acceptable salt thereof. The dosage of the drug delivered is proportional to the size of the patch applied and achieves 60-85% platelet inhibition. The system enables and individualized treatment for patients. Also provided are methods for the treatment of various disorders where platelet inhibition is desired.

Abstract: The present invention includes use of an angiotensin-converting enzyme (ACE) inhibitor in combination with a vitamin B6 related compound for the treatment of diabetes and diabetic related disorders and in particular the treatment of diabetic hypertension.

Abstract: The present invention provides a method of administering vitamin B6 related compounds for treatment of hypertriglyceridemia. Vitamin B6 related compounds include pyridoxal, pyridoxal-5?-phosphate, pyridoxamine, a 3-acylated analogue of pyridoxal, a 3-acylated analogue of pyridoxal-4,5-aminal, and mixtures thereof. Embodiments of the present invention also comprise co-administering a lipid lowering agent, such as a nicotinic acid, a fibrate, a HMG CoA reductase inhibitor, a cholesteryl ester transfer protein inhibitor, and combinations thereof.

Abstract: The present invention is directed to oligonuclegtides comprising nucleotide sequences sufficiently complementary to conserved regions of human immunodeficiency virus genetic material such that when bound to said region, the oligonucleotides effectively prevent expression of the genetic material.

Abstract: The present invention is directed to oligonucleotides comprising nucleotide sequences sufficiently complementary to conserved regions of human immunodeficiency virus genetic material such that when bound to said region, the oligonucleotides effectively prevent expression of the genetic material.

Abstract: The present invention is directed to oligonucleotides comprising nucleotide sequences sufficiently complementary to conserved regions of human immunodeficiency virus genetic material such that when bound to said region, the oligonucleotides effectively prevent expression of the genetic material.

Abstract: A sight tube for ultraviolet monitoring of liquid and capable of handling industrial scale flow rates for example 40 gallons (180 liters) per minute in which the shape is especially designed to allow oppositely disposed windows, through which the ultraviolet light passes, to be relatively close together. The sight tube has an interior the central section of which has a flat sided portion adjacent and parallel to the windows, the flat sided portion being flanked by two side portions which are thicker than said flat sided portion, the tube having cylindrical end sections joined to the central section by intermediate sections which provide gradual transitions between the section shapes.